Current Multimodality Treatments Against Brain Metastases from Renal Cell Carcinoma

Area of Science:

• Oncology
• Neurosurgery
• Radiotherapy

Background:

• Brain metastasis is a significant poor prognostic factor in renal cell carcinoma (RCC).
• Systemic treatments, including molecular targeted therapy and immune checkpoint inhibitors, have improved survival in metastatic RCC, but often excluded patients with brain metastasis.
• Increased survival due to better extra-cranial disease control leads to a rising incidence of brain metastasis in clinical practice.

Purpose of the Study:

• To review the recent advancements in the multimodality treatment of brain metastasis from renal cell carcinoma.
• To explore the efficacy and safety of novel systemic agents in patients with brain metastasis.
• To discuss the role of advanced local treatments, particularly stereotactic radiosurgery, in combination with systemic therapies.

Main Methods:

• Systematic literature review of prospective and retrospective studies.
• Analysis of subgroup data focusing on brain metastasis in renal cell carcinoma clinical trials.
• Evaluation of treatment outcomes for combined systemic and local therapies.

Main Results:

• Accumulating data on risk classification and treatment efficacy for brain metastasis in RCC.
• Evidence suggesting improved outcomes with the combination of systemic therapy and advanced local treatments.
• Stereotactic radiosurgery shows particular promise when combined with molecular targeted therapy or immune checkpoint inhibitors.

Conclusions:

• The combination of systemic therapy and advanced local treatments represents a promising strategy for managing brain metastasis in renal cell carcinoma.
• Further research and clinical trials are needed to optimize multimodality treatment protocols.
• Improved patient survival in metastatic RCC necessitates better management strategies for brain metastases.